Navigation Links
Applied BioMath, LLC announces collaboration with Zymeworks Inc. for Clinical Trial Support in Oncology
Date:3/29/2017

LINCOLN, Mass., March 29, 2017 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced an extension of their collaboration with Zymeworks Inc. for quantitative systems pharmacology (QSP) support for antibody drug conjugate therapeutics intended for the treatment of cancer.

Applied BioMath has supported Zymeworks previously for GLP toxicology studies and first-in-human dose predictions for IND filings.   This extension of their collaboration will update the previously built QSP model with new clinical data to analyze and predict dose escalations and inform internal decisions about next steps in clinical trials.  "One of the benefits of our modeling approach is that we can easily evolve our model as new data is produced to continue to support the project team throughout R&D," said John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath.  "We prioritize an accurate representation of the disease biology specifically for this reason, so that the model translates well from early development to the clinic."

"We are pleased to extend our collaboration with Applied BioMath," said Gerry Rowse, PhD, Senior Director, Therapeutics Preclinical Development, Zymeworks. "The mechanistic modeling work the Applied BioMath team continues to perform significantly contributes to our R&D efforts and decision making processes. We look forward to continuing our working relationship with them as we advance our programs into clinical trials."

About Applied BioMath

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, helps biotechnology and pharmaceutical companies answer complex, critical Go/No-go decisions in R&D.  Applied BioMath leverages biology, proprietary mathematical modeling and analysis technology, high-performance computing, and decades of industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, and the best path forward.   Our involvement shortens project timelines, lowers cost, and increases the likelihood of a best-in-class drug.  We provide clarity to complex situations, answer otherwise unanswerable questions, and our approach, when validated in the clinic, is 10x more accurate than traditional methodologies.

Applied BioMath and the Applied BioMath logo are trademarks of Applied BioMath, LLC.

Press contact:
Kristen Zannella
kristen.zannella@appliedbiomath.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/applied-biomath-llc-announces-collaboration-with-zymeworks-inc-for-clinical-trial-support-in-oncology-300431112.html


'/>"/>
SOURCE Applied BioMath
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Applied BioMath, LLC and CytomX Therapeutics, Inc. announce a collaboration to develop a Quantitative Systems Pharmacology Probody platform model for use in lmmuno-Oncology
2. Applied BioMath, LLC presents work in immuno-oncology and antibody drug-conjugates at Keystone Symposium
3. Applied BioMath, LLC to present at Boston Area Group for Informatics and Modeling Meeting
4. Applied Biophysics Engages ibidi USA as Manufacturer’s Representative in the US and Canada
5. Pittcon Solicits Call for Nominations for 2017 Awards in Areas of Analytical Chemistry and Applied Spectroscopy
6. Applied BioPhysics Introduces pFlow Peristaltic Pump
7. Dr. Joseph Loscalzo, MD, PhD announced as newest member of the Applied BioMath Scientific Advisory Board
8. Applied BioMath, LLC. To Sponsor and Present at QSP Congress Boston 2015
9. Pittcon Recognizes Achievements in Analytical Chemistry and Applied Spectroscopy
10. Applied Silicone Launches Silicone Gel System with Dual Matrix Technology
11. Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2019)... (PRWEB) , ... May 29, ... ... our patent applications from the USPTO providing proprietary interest to our methodology, ... FOR SLEEP DISORDER DIAGNOSIS AND TREATMENT… extends Somnology’s IP rights including our ...
(Date:5/31/2019)... ... May 30, 2019 , ... A study released today in ... for the sustained release of human placental stem cell (HPSC)-derived conditioned medium (CM) ... deliver CM into the injured kidney, where it helped restore function and regenerate ...
(Date:5/15/2019)... , ... May 15, 2019 , ... Milton Hershey School® ... recognition for his work within the biomedical industry, where he is changing lives by ... devices. , “William Harding epitomizes the vision of our founders – Milton and ...
(Date:5/14/2019)... , ... May 14, 2019 , ... Gateway Genomics ... effectively doubling its space from 2,500 to 5,000 square feet. , “This past ... DNA tests ,” says Gateway Genomics CEO, Chris Jacob. “The SneakPeek At-Home test, which ...
Breaking Biology Technology:
(Date:5/31/2019)... VIEJO, Calif. (PRWEB) , ... May 30, 2019 ... ... leading clinical genetics testing company, and Mayo Clinic, have documented significant differences in ... cancer among racial and ethnic populations compared to non-Hispanic White women. Results will ...
(Date:5/31/2019)... Kan. (PRWEB) , ... May 30, 2019 , ... Enso ... year, and especially during Military Appreciation Month, as a way to express his gratitude ... Patrick, and the company he founded — Enso Discoveries — presented a ...
(Date:5/26/2019)... ... May 24, 2019 , ... Zolgensma (Novartis, AveXis), an AAV-delivered gene therapy used ... use in the United States by the Food and Drug Administration today. ... inherited genetic disorders in the United States and the second-ever approved treatment for SMA. ...
Breaking Biology News(10 mins):